BeyondSpring recorded R&D expenses of $1.1M for Q1 2026, up from $0.9M a year earlier primarily due to increased drug manufacturing activities. G&A expenses fell to $1.1M from $1.7M as personnel and advisory costs declined, resulting in a net loss of $2.4M versus $2.6M in Q1 2025, with cash, cash equivalents and short-term investments totaling $7.9M and discontinued operations reporting a $4.3M loss.

Preclinical data presented at AACR 2026 demonstrated that Plinabulin significantly improved complete response rates, survival outcomes and tolerability when combined with topoisomerase inhibitor–based ADC therapies, also enhancing the CD8+ T cell/Treg ratio to shift the tumor microenvironment toward an immune-active state, supporting its role as a backbone combination agent.

SEED’s novel RBM39 molecular glue degrader ST-01156 advanced into Phase 1 oncology trials with the first dose cohort completed. In vivo neuroblastoma models achieved complete tumor eradication, and MYC overexpression along with CDKN2A/B deletion were identified as predictive biomarkers, highlighting the RITE3™ platform’s precision oncology potential.